ChromaDex (NASDAQ:CDXC) Earns “Buy” Rating from HC Wainwright

ChromaDex (NASDAQ:CDXC)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $11.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 39.77% from the company’s previous close.

A number of other research analysts have also recently commented on the stock. LADENBURG THALM/SH SH upped their target price on shares of ChromaDex from $6.80 to $8.10 and gave the company a “buy” rating in a research report on Wednesday, March 5th. StockNews.com cut shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 6th.

ChromaDex Price Performance

NASDAQ CDXC opened at $7.87 on Monday. The firm’s 50-day moving average is $6.11 and its two-hundred day moving average is $5.42. ChromaDex has a 12 month low of $2.31 and a 12 month high of $9.18. The stock has a market capitalization of $611.89 million, a P/E ratio of 787.79 and a beta of 2.21.

Institutional Trading of ChromaDex

Institutional investors and hedge funds have recently bought and sold shares of the business. USA Financial Formulas purchased a new stake in ChromaDex during the fourth quarter worth about $25,000. State of Wyoming purchased a new stake in ChromaDex during the fourth quarter worth about $39,000. Mercer Global Advisors Inc. ADV purchased a new stake in ChromaDex during the fourth quarter worth about $53,000. Truist Financial Corp purchased a new stake in ChromaDex during the fourth quarter worth about $54,000. Finally, Schonfeld Strategic Advisors LLC purchased a new stake in ChromaDex during the fourth quarter worth about $67,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.